Eli Lilly ramps up its fight against imitation weight-loss drugs

The maker of blockbuster appetite-suppressing drugs Mounjaro and Zepbound is seeking to end a regulatory designation that has allowed cheaper, off-brand versions to flourish.

View original article
Contributor: Daniel Gilbert